EG Labo
EG Labo is a French pharmaceutical laboratory and wholly-owned subsidiary of STADA Group that commercializes the third-largest generic medicines portfolio in France, OTC consumer health products, and biosimilars through the French pharmacy network.
- Company typePrivate
- Founded1996
- HeadquartersIssy-les-moulineaux, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What EG Labo does
EG Labo (legally Laboratoires EuroGenerics SAS) is a French pharmaceutical laboratory founded in 1996 and headquartered in Issy-les-Moulineaux, operating as a wholly-owned subsidiary of Germany's STADA Arzneimittel AG. The company commercializes over 820 pharmaceutical products across three pillars: specialty generic medicines (the third-largest generic portfolio in the French market), consumer health/OTC products including the Mitosyl and SyntholOral brands, and biosimilars across rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic therapeutic areas. The company reports 40 million units sold annually through its 103 employees in France and serves pharmacies, physicians, pharmacists, and end patients via a sales-led go-to-market focused on tailored strategies for healthcare professionals.
The underlying technology is traditional pharmaceutical product development and regulatory-compliant commercialization rather than a proprietary digital platform; EG Labo relies on STADA Group's R&D pipeline and biosimilar development capabilities rather than independent proprietary technology assets. Revenue mechanics are generated through pharmacy procurement of prescription generics, OTC consumer health products, and biosimilars, all distributed through the French pharmacy network under regulated French national health system pricing. The company's commercial moat rests on portfolio breadth (covering all major therapeutic classes), 29 years of pharmacy channel relationships, and STADA Group's regulatory and biosimilar expertise.
EG Labo's strategic posture is defensive on generics scale and offensive on biosimilars, evidenced by the March 2025 launch of Ximluci (ranibizumab biosimilar), expansion of its biosimilar portfolio to four commercialized products, and proactive pharmacovigilance investments such as the December 2025 valproate pregnancy prevention program update. The company is also investing in HR practices, earning Top Employer France 2026 certification for the first time, suggesting organizational development aligned with STADA's broader European growth strategy.
EG Labo firmographics
Firmographics- Name
- EG Labo
- Legal name
- EG LABO - Laboratoires EuroGenerics
- Website
- https://eglabo.fr
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- EG Labo is a French pharmaceutical laboratory and wholly-owned subsidiary of STADA Group that commercializes the third-largest generic medicines portfolio in France, OTC consumer health products, and biosimilars through the French pharmacy network.
- Ownership category
- akta.pro rank
EG Labo industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where EG Labo is headquartered
LocationHeadquarters
- HQ city
- Issy-les-moulineaux
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
EG Labo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Generic Pharmaceuticals: EG Labo operates as a generic pharmaceutical laboratory with the third largest generic portfolio in the French market, offering specialty generics covering major therapeutic classes. Revenue is generated through pharmacy sales of prescription generic medications.
- OTC/Consumer Healthcare: EG Labo develops over-the-counter medicines, non-reimbursable reference products, and family health brands including skincare, dietary supplements, cosmetics, and medical devices sold through pharmacies.
- Biosimilars: As part of STADA Group, EG Labo commercializes biosimilar medications in France, currently with four biosimilars available, focusing on rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic therapeutic areas.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
EG Labo product offering
Product offeringCore offering
EG Labo is a French pharmaceutical laboratory that manufactures and distributes a broad portfolio of generic medicines, over-the-counter (OTC) consumer health products, and biosimilars. The company holds the third largest generic drug portfolio in the French market, covering all major therapeutic classes with more than 820 products and approximately 40 million units sold annually. Its product range is sold exclusively through French pharmacies and includes specialty generics, family health brands, skincare, dietary supplements, cosmetics, and medical devices.
Product overview
EG Labo (Laboratoires EuroGenerics) is a pharmaceutical company and subsidiary of STADA Group, offering a comprehensive portfolio of generic medications, consumer health products, non-reimbursable reference drugs, and biosimilars. The product portfolio includes three main lines: (1) Spécialités Génériques EG - the third-largest generic drug range in the French market; (2) Santé Grand Public - OTC medications, reference specialties, skincare, supplements, cosmetics, and medical devices; and (3) Biosimilaires - biosimilar medications across rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic areas. The company commercializes over 820 products with 40 million units sold annually, supported by 103 employees and 29 years of experience.
Differentiator
Problem solved
Functional benefit
Products and services
- Spécialités Génériques EG EG Labo's core generic pharmaceuticals portfolio, comprising the third-largest range of generic drugs in the French market and covering all major therapeutic classes for dispensing through pharmacies.
- Santé Grand Public Consumer health product line offering OTC medications, non-reimbursable reference drugs, family health brands, skincare products, dietary supplements, cosmetics, and medical devices sold through French pharmacies.
- Biosimilaires Biosimilar medications across multiple therapeutic areas including rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic treatments, with four biosimilars currently commercialized in France.
- Mitosyl Well-known family health product brand under the EG Labo portfolio, focused on baby care products including creams, roll-on, and wipes.
- SyntholOral Consumer health brand for oral health products distributed in France through the pharmacy network.
Quantifiable outcome
- 40 million units sold per year across 820 products
- +2 more outcomes
Companies that use EG Labo
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
EG Labo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EG Labo partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- STADA Group (Groupe STADA)coreEG Labo is a wholly-owned subsidiary of STADA Arzneimittel AG, a German pharmaceutical company headquartered in Bad Vilbel, Germany. STADA operates with three strategic pillars: Consumer Healthcare, Generics, and Specialty products. EG Labo represents the French operations of the STADA Group, benefiting from the group's portfolio, R&D capabilities, and biosimilar development expertise. STADA reported €4.3 billion in adjusted revenue in 2025 with 11,749 employees worldwide.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
EG Labo competitors and assessment
Company assessmentDirect peers
- Biogaran: Biogaran is the leading French generic pharmaceutical laboratory and a subsidiary of Servier. It directly competes with EG Labo for pharmacy shelf space across the same generic therapeutic classes in the French market, operating an identical pharmacy-led distribution model.
- Arrow Génériques (Aurobindo): Arrow Génériques is one of the leading French generic pharmaceutical companies and part of Aurobindo Group. It competes head-to-head with EG Labo in the French generic market with comparable portfolio breadth and a pharmacy distribution model.
- Cristers: Cristers is a French generic pharmaceutical laboratory offering a broad portfolio across therapeutic classes. It competes directly with EG Labo for the same pharmacy customers with a similar price-led generic value proposition.
- Zentiva: Zentiva is a major European generic and OTC pharmaceutical company headquartered in Prague, with significant presence in France. It competes with EG Labo across generics and OTC consumer health products across similar therapeutic areas.
Broad incumbents
- Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical company with significant French operations (Teva Santé). It competes directly with EG Labo in generic medicines across the same therapeutic classes while also offering biosimilars, OTC and specialty products at a global scale.
- Sandoz: Sandoz is the global leader in generics and biosimilars, spun off from Novartis in 2023. It is a major peer in both generic pharmaceuticals and biosimilars, including the same therapeutic categories EG Labo addresses (immunology, oncology).
- Mylan/Viatris: Viatris (formed by Mylan-Upjohn merger) is a global pharmaceutical company with a strong generics franchise including French operations. It is comparable to EG Labo in generics and biosimilars but at much larger scale across multiple geographies.
Emerging players
- Krka: Krka is a Slovenian generic pharmaceutical company with significant European footprint. It overlaps with EG Labo in generic prescription medicines and is expanding in biosimilars, making it a comparable specialty generic manufacturer in European markets.
Others
- Stada Arzneimittel AG (parent): STADA is EG Labo's parent company and the relevant comparison point for the broader portfolio strategy, R&D and biosimilar capabilities. As the same group, STADA represents the full upstream source of products and capabilities that flow down to EG Labo.
Regional players
- Almus Pharmaceuticals: Almus is a European generics brand focused on pharmacy-channel generic medicines. While smaller in France, it operates with a comparable pharmacy-only distribution model and similar generic portfolio positioning, making it an adjacent competitive reference.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
EG Labo social profiles
Digital presenceEG Labo compliance and trust
Trust signalCompliance3 records
EG Labo financial estimates
Financial estimateRevenue estimate
Valuation estimate
EG Labo leadership team
Management profileNumber of profiles
Profiles6 records
EG Labo subsidiaries and ownership
Company hierarchySubsidiaries2 records
EG Labo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EG Labo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EG Labo
What does EG Labo do?
EG Labo is a French pharmaceutical laboratory that manufactures and distributes a broad portfolio of generic medicines, over-the-counter (OTC) consumer health products, and biosimilars. The company holds the third largest generic drug portfolio in the French market, covering all major therapeutic classes with more than 820 products and approximately 40 million units sold annually. Its product range is sold exclusively through French pharmacies and includes specialty generics, family health brands, skincare, dietary supplements, cosmetics, and medical devices.
Is EG Labo a public or private company?
EG Labo is a private company. It is classified as corporate owned and is currently operating.
When was EG Labo founded?
EG Labo was founded in 1996. It employs 101 to 250 people.
Where is EG Labo based?
EG Labo is headquartered in Issy-les-moulineaux, France, in the Europe region.
How does EG Labo make money?
Three revenue lines are on record. Generic Pharmaceuticals are the primary driver. The others are OTC/Consumer Healthcare and biosimilars.
Who are EG Labo's main competitors?
Direct peers on record are Biogaran, Arrow Génériques (Aurobindo), Cristers and Zentiva. Broad incumbents are Teva Pharmaceutical Industries, Sandoz and Mylan/Viatris. Krka is listed as an emerging player. Stada Arzneimittel AG (parent) is listed as an others. Almus Pharmaceuticals is listed as a regional player.
Does EG Labo have an API?
No public API is recorded for EG Labo.
What industry is EG Labo in?
EG Labo's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.